Publish in this journal
Journal Information
Vol. 74. Issue 2.
Pages 205-206 (February 2021)
Corrections
DOI: 10.1016/j.rec.2020.09.032
Full text access
Correction in article by Bonanad et al. “Coronavirus: the geriatric emergency of 2020. Joint document of the Section on Geriatric Cardiology of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology”, Rev Esp Cardiol. 2020;73:569-576
Corrección en el artículo de Bonanad et al. «Coronavirus: la emergencia geriátrica de 2020. Documento conjunto de la Sección de Cardiología Geriátrica de la Sociedad Española de Cardiología y la Sociedad Española de Geriatría y Gerontología», Rev Esp Cardiol. 2020;73:569-576
Visits
...
Related content
Rev Esp Cardiol. 2020;73:569-7610.1016/j.rec.2020.05.001
Clara Bonanad, Sergio García-Blas, Francisco José Tarazona-Santabalbina, Pablo Díez-Villanueva, Ana Ayesta, Juan Sanchis Forés, María Teresa Vidán-Austiz, Francesc Formiga, Albert Ariza-Solé, Manuel Martínez-Sellés
This item has received
...
Visits
(Daily data update)
Article information
Full Text
Download PDF
Statistics
Tables (1)
Table 3. Adverse cardiovascular effects of drugs investigated for COVID-19 treatment
Full Text

Several errors were detected in the English translation of table 3 of the article “Coronavirus: the geriatric emergency of 2020. Joint document of the Section on Geriatric Cardiology of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology”. The correct table is:

Table 3.

Adverse cardiovascular effects of drugs investigated for COVID-19 treatment

Chloroquine/hydroxychloroquine  Use carefully in patients with previous heart deasese, with QT at the upper limit of normal or on treatment with QT interval-prolonging agents,* electrolyte abnormalities (particularly hypokalemia or hypomagnesemia), clinically-relevant bradycardia, arrhythmia, or severe heart failure. 
  The dosage must be adjusted in chronic kidney disease (glomerular filtration rate <50 mL/min). 
Lopinavir/ritonavir  Use carefully in patients with previous heart disease, with QT already at the upper limit of normal or on treatment with QT interval-prolonging agents*, electrolyte abnormalities (particularly hypokalemia or hypomagnesemia), clinically-relevant bradycardia, arrhythmia, or severe heart failure. 
Azithromycin  Chronic kidney disease, fulminant hepatitis; carefully in patients with arrhythmogenic disease (particularly female and elderly patients), congenital or confirmed QT interval prolongation,* electrolyte abnormalities (particularly hypokalemia or hypomagnesemia), clinically-relevant bradycardia, arrhythmia, or severe heart failure. 
Remdesivir  Hypotension during infusion. Unknown CV interactions. 
Tocilizumab  Hypertriglyceridemia, elevated transaminases. Unknown CV interactions. 
Interferon β-1b  Flu-like illness. Liver failure. No CV interactions reported. 
Cyclosporin  Hypertension, hyperlipidemia, hyperuricemia, hyperkalemia, hypomagnesemia. 

CV, cardiovascular.

*

QT interval-prolonging agents: class I A (quinidine and procainamide) and III (dofetilide, amiodarone, and sotalol) antiarrhythmics, cisapride, terfenadine, antipsychotics such as pimozide, antidepressants such as citalopram, and fluoroquinolones such as moxifloxacin and levofloxacin.

This correction has been made in the electronic version of the article on 12 October.

Copyright © 2020. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?